Literature DB >> 8756387

Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study.

T Ozaki1, A Hillmann, C Hoffmann, C Rübe, S Blasius, J Dunst, H Jürgens, W Winkelmann.   

Abstract

BACKGROUND: There is little information regarding an adequate surgical margin for local control of Ewing's sarcoma.
METHODS: Two hundred and forty-four patients (PTS) with Ewing's sarcoma who were registered in the Cooperative Ewing's Sarcoma Studies underwent surgical treatment. Ninety-four PTS underwent definitive surgery (surgery alone), 131 PTS received postoperative irradiation, and 19 PTS received preoperative irradiation. The surgical margins were distributed as follows: radical, 29 PTS; wide, 148 PTS; marginal, 39 PTS; and intralesional, 28 PTS. The impact of the surgical margin on the treatment outcome of PTS was analyzed statistically.
RESULTS: The local or combined (local recurrence and systemic metastasis) relapse rate after surgery with or without irradiation was significantly lower compared with that after definitive irradiation (irradiation alone) (7% vs. 31%, P < 0.0001). The local or combined relapse rate after complete resection (radical or wide margin) with or without irradiation was less compared with that after incomplete resection (marginal or intralesional margin) with or without irradiation (5% vs. 12% P = 0.0455). The local or combined relapse rate did not greatly decreased after irradiation after incomplete surgery (from 14% to 12%). In both groups of good (viable tumor cells < 10%) and poor (viable cells > or = 10%) histologic response, the difference in systemic or combined relapse rate between patients undergoing complete and incomplete surgery was not significant. The 10-year overall survival of the PTS for each of the margins was distributed as follows: radical, 58%; wide, 65%; marginal, 61%; and intralesional, 71% (P = not significant).
CONCLUSIONS: Surgery in patients with Ewing's sarcoma adds to the safety of local control. Under the current treatment regimen with intensive chemotherapy and irradiation, complete resection of the tumor appears capable of decreasing the risk of local recurrence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756387     DOI: 10.1002/(SICI)1097-0142(19960815)78:4<892::AID-CNCR29>3.0.CO;2-P

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Multidisciplinary management of primary tumors of the vertebral column.

Authors:  Wesley Hsu; Thomas A Kosztowski; Hasan A Zaidi; Michael Dorsi; Ziya L Gokaslan; Jean-Paul Wolinsky
Journal:  Curr Treat Options Oncol       Date:  2009-06-23

2.  Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group.

Authors:  Steven G DuBois; Mark D Krailo; Mark C Gebhardt; Sarah S Donaldson; Karen J Marcus; John Dormans; Robert C Shamberger; Scott Sailer; Richard W Nicholas; John H Healey; Nancy J Tarbell; R Lor Randall; Meenakshi Devidas; James S Meyer; Linda Granowetter; Richard B Womer; Mark Bernstein; Neyssa Marina; Holcombe E Grier
Journal:  Cancer       Date:  2014-09-23       Impact factor: 6.860

3.  Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Robert Mennel; Carl Lenarsky; Staci Horvath; Gladice Wallraven; Beena O Pappen; Sam Whiting; Donald Rao; Neil Senzer; John Nemunaitis
Journal:  Mol Ther       Date:  2016-04-25       Impact factor: 11.454

4.  Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study.

Authors:  Sarah E Bosma; Arjen H G Cleven; P D Sander Dijkstra
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

5.  [18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma.

Authors:  Alessio Annovazzi; Virginia Ferraresi; Vincenzo Anelli; Renato Covello; Sabrina Vari; Carmine Zoccali; Roberto Biagini; Rosa Sciuto
Journal:  Eur Radiol       Date:  2021-03-13       Impact factor: 5.315

6.  Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing's sarcoma family of tumors.

Authors:  Shintaro Iwata; Tsukasa Yonemoto; Takeshi Ishii; Kyoya Kumagai; Reiko Imai; Yoko Hagiwara; Tadashi Kamada; Shin-Ichiro Tatezaki
Journal:  Int J Clin Oncol       Date:  2012-10-03       Impact factor: 3.402

Review 7.  Soft-tissue sarcoma in adolescents and young adults.

Authors:  Toshiyuki Kunisada; Eiji Nakata; Tomohiro Fujiwara; Ako Hosono; Shota Takihira; Hiroya Kondo; Toshifumi Ozaki
Journal:  Int J Clin Oncol       Date:  2022-01-27       Impact factor: 3.402

Review 8.  Diagnosis and treatment of Ewing sarcoma of the bone: a review article.

Authors:  Toshifumi Ozaki
Journal:  J Orthop Sci       Date:  2015-02-19       Impact factor: 1.601

9.  Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.

Authors:  Katsutsugu Umeda; Takako Miyamura; Kenji Yamada; Hideki Sano; Ako Hosono; Minako Sumi; Hajime Okita; Tadashi Kumamoto; Akira Kawai; Junya Hirayama; Ryoji Jyoko; Akihisa Sawada; Hideki Nakayama; Yosuke Hosoya; Naoko Maeda; Nobuyuki Yamamoto; Chihaya Imai; Daiichiro Hasegawa; Motoaki Chin; Toshifumi Ozaki
Journal:  Cancer Rep (Hoboken)       Date:  2021-01-16

10.  A peripheral primitive neuroectodermal tumor originating from the pancreas: a case report and review of the literature.

Authors:  Nobuyuki Nishizawa; Yusuke Kumamoto; Kazuharu Igarashi; Ryo Nishiyama; Hiroshi Tajima; Hiroshi Kawamata; Takashi Kaizu; Masahiko Watanabe
Journal:  Surg Case Rep       Date:  2015-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.